Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 6/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23710200 | 1.00 | TSHR (0.54) | TSHRRECQLPDK1GAAENPP2 | |
| SCHEMBL23710005 | 1.00 | TSHR (0.54) | TSHRRECQLPDK1GAAENPP2 | |
| SCHEMBL23710002 | 0.87 | TSHR (0.51) | TSHRRECQLPDK1GAAENPP2 | |
| SCHEMBL7371870 | 0.87 | TSHR (0.51) | TSHRRECQLPDK1GAAENPP2 | |
| SCHEMBL22167707 | 0.87 | PDK1 (0.45) | TSHRRECQLPDK1ENPP2HTT | |
| SCHEMBL22167711 | 0.87 | PDK1 (0.45) | TSHRRECQLPDK1ENPP2HTT | |
| SCHEMBL23710198 | 0.87 | PDK1 (0.45) | TSHRRECQLPDK1ENPP2HTT | |
| SCHEMBL11122904 | 0.85 | LMNA (0.55) | TSHRRECQLPDK1ENPP2POLB | |
| SCHEMBL10172553 | 0.83 | USP2 (0.53) | RECQLPDK1ALDH1A1SMN1; SMN2THRB | |
| SCHEMBL10172566 | 0.83 | USP2 (0.53) | RECQLPDK1ALDH1A1SMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858832-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | TSHR 4461/4885RECQL 3677/4885PDK1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.